Commissariat a L'energie Atomique Et Aux Energies Alternatives

Centre National De La Recherche Scientifique

Institut Curie

Commissariat a L'energie Atomique

University of Texas System

Commissariat À L'énergie Atomique Et Aux Énergies Alternatives

Centre National De La Recherche Scientifique-cnrs

Daniel Gillet

Julien Barbier

Jean-Christophe Cintrat

Ludger Johannes

Thomas Rudel

Jo-Ana Herweg

Annette Fischer

Andre Menez

Jean-Claude Boulain

Frederic Ducancel

Bahne Stechmann

Siau-Kun Bai

Paul Boquet

Romain Noel

Bernard Maillere

Robert A Davey

Alain Sanson

Valérie Pons

Benoit Villiers

Alain Pruvost

Sylvain Pichard

Audrey Couhert

Hajer Abdelkafi

Robin Vinck

Livia Tepshi

Karen Hinsinger

The invention relates to a new family of compounds of the type 2,3-dihydroquinazolin-4(1H)-one and the use thereof as inhibitors of the toxic effects of intracellular-acting toxins, such as ricin, Shiga toxins or the cholera toxin, using retrograde transport to intoxicate the cells, or viruses or bacteria using retrograde and/or syntaxin 5-dependent transport to infect the cells, specifically viruses or bacteria entering into the cells by means of endocytosis, or intracellular parasites.

Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria

The invention relates to a method for treating a Chlamidyales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: Wherein R, R, Rand Ar are as defined in claim

Benzodiazepine derivatives for use in the treatment of Chlamydiales infections

The present invention relates to a method for treating a Chlamydiales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof:W-L-NH-L-Ar&#x2003;&#x2003; (I)Wherein W, L1, L2 and Ar are as defined in claim

Adamantane or pinene derivatives for use in the treatment of chlamydiales infections

A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.

HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway

Use of 2,3-dihydroquinazolin-4(1H)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus. 

2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections

The present invention relates to a method for treating a Chlamydiae infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: Wherein, R1, R2, R3, R4 and p are as defined in claim

Quinazolinone derivatives for use in the treatment of chlamydiales infections

The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, for example, using retrograde transport to intoxicate cells.

Compounds having a protective activity against toxins with intracellular activity

The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.

Inhibitors of the shiga toxins trafficking through the retrograde pathway

Inhibitors of the Shiga toxins trafficking through the retrograde pathway

A kit for carrying out an immunoenzymological assay for protein, containing a diagnostic reagent consisting of a hybrid protein comprising, in order, a polypeptide P1 which is an N-terminal portion of mature alkaline phosphatase comprising from 6 to 28 of the N-terminal amino acids of said mature alkaline phosphatase, joined to a polypeptide P2, capable of interacting with an antibody or antigen joined to a polypeptide P3 which is selected from the group consisting of a) the C-terminal remaining amino acids of said mature alkaline phosphatase, b) the mature sequence of alkaline phosphatase, and c) enzymatically active fragments of b).

Hybrid proteins between an extracytoplasmic enzyme and at least another

The disclosed invention involves a DNA encoding a hybrid tripartite protein comprising an amino portion consisting of from 6 to 28 amino acid residues from the N-terminal of a mature E. coli alkaline phosphatase, a central portion corresponding to a heterologous polypeptide and a carboxyl portion which consists of the remainder of the mature E. coli alkaline phosphatase, a different alkaline phosphatase or an enzymatically active fragment of either. The tripartite proteins produced with this DNA can be used as a diagnostic reagent and in the screening of nucleic acid libraries or in the selection of recombinant clones.

Growing community of inventors

Antony, France

Daniel Gillet